A recent meta-analysis of 38 clinical trials involving 2254 patients confirmed that QYD dramatically lowered levels of proinflammatory factors, including interleukin- (IL-) 6, tumor necrosis factor-α (TNF-α), and IL-1β while increasing levels of the anti-inflammatory factor IL-10 in patients with AP [5]. This evidence concerns the gene TNF and alkaline phosphatase measurement.